Walder Wyss advised Versant Ventures in Matterhorn Biosciences launching

Matterhorn Biosciences, a Swiss biotechnology company developing T cell receptor therapies based on the recent discovery of MR1T cells that recognize and kill a wide range of tumors of various tissue origins, has received a financing of USD 30 million from Versant Ventures. It is the most recent company to be launched out of Versant’s Ridgeline Discovery Engine based in Basel, Switzerland.

The advisor

Walder Wyss advised Versant Ventures in connection with this transaction. The team was led by partner  Alexander Gutmans (Transaction/M&A & Venture Capital – pictured) and partner Robert von Rosen (Transaction/M&A & Venture Capital) and included partner Markus R. Frick (IP/IT), senior associate Jessica Aeschbach Flórez (Transaction/M&A) and associate Karina Tschon (Transaction/M&A).

Walder Wyss advised Versant Ventures in Matterhorn Biosciences launching



Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram